Suppr超能文献

准分子激光原位角膜磨镶术(LASIK)在矫正近视方面比光性屈光性角膜切削术具有更高疗效和安全性的证据。

Evidence for superior efficacy and safety of LASIK over photorefractive keratectomy for correction of myopia.

作者信息

Shortt Alex J, Bunce Catey, Allan Bruce D S

机构信息

Moorfields Eye Hospital, London, United Kingdom.

出版信息

Ophthalmology. 2006 Nov;113(11):1897-908. doi: 10.1016/j.ophtha.2006.08.013.

Abstract

PURPOSE

To examine possible differences in efficacy and safety between LASIK and photorefractive keratectomy (PRK) for correction of myopia.

DESIGN

Meta-analysis/systematic review.

PARTICIPANTS

Patient data from previously reported prospective randomized controlled trials (PRCTs) and a systematic review of prospective case series in the Food and Drug Administration (FDA) clinical trials database.

METHODS

A comprehensive literature search was performed using the Cochrane Collaboration methodology to identify PRCTs comparing LASIK and PRK for correction of myopia. A meta-analysis was performed on the results of PRCTs. In parallel, a systematic review of prospective data from FDA case series of LASIK and PRK for correction of myopia was undertaken.

MAIN OUTCOME MEASURES

Key efficacy outcomes (uncorrected visual acuity [UCVA] > or = 20/20, +/-0.50 diopters [D] of the target mean refractive spherical equivalent) and safety outcomes (loss of > or =2 lines of best spectacle-corrected visual acuity [BSCVA], final BSCVA > or = 20/40, and final BSCVA < 20/25 where preoperative BSCVA was > or =20/20).

RESULTS

Seven PRCTs were identified comparing PRK (683 eyes) and LASIK (403 eyes) for correction of myopia. More LASIK patients achieved UCVA > or = 20/20 at 6 months (odds ratio, random effects model [95% confidence interval], 1.72 [1.14-2.58]; P = 0.009) and 12 months (1.78 [1.15-2.75], P = 0.01). Loss of > or =2 lines of BSCVA at 6 months was less frequent with LASIK (2.69 [1.01-7.18], P = 0.05). Data from 14 LASIK (7810 eyes) and 10 PRK (4414 eyes) FDA laser approval case series showed that more LASIK patients achieved UCVA of 20/20 or better at 12 months (1.15 [1.03-1.29], P = 0.01), significantly more LASIK patients were within +/-0.50 D of target refraction at 6 months (1.38 [1.26-1.50], P<0.00001) and 12 months (1.21 [1.08-1.36], P = 0.0009) after treatment, and loss of > or =2 lines of BSCVA at 6 months was less frequent with LASIK (2.91 [2.22-3.83], P<0.00001).

CONCLUSIONS

LASIK appears to have efficacy and safety superior to those of PRK. However, the data examined are from studies conducted > or =5 years ago. It is therefore unclear how our findings relate to present-day methods and outcomes. Further trials comparing contemporary equipment and techniques are needed to reevaluate the relative merits of these procedures.

摘要

目的

探讨准分子原位角膜磨镶术(LASIK)与准分子激光角膜切削术(PRK)矫正近视在疗效和安全性上的可能差异。

设计

荟萃分析/系统评价。

研究对象

来自先前报道的前瞻性随机对照试验(PRCT)的患者数据以及对美国食品药品监督管理局(FDA)临床试验数据库中前瞻性病例系列的系统评价。

方法

采用Cochrane协作网方法进行全面的文献检索,以识别比较LASIK和PRK矫正近视的PRCT。对PRCT的结果进行荟萃分析。同时,对FDA关于LASIK和PRK矫正近视的病例系列中的前瞻性数据进行系统评价。

主要观察指标

关键疗效指标(裸眼视力[UCVA]≥20/20,目标平均等效球镜度±0.50屈光度[D])和安全性指标(最佳矫正视力[BSCVA]下降≥2行,最终BSCVA≥20/40,以及术前BSCVA≥20/20时最终BSCVA<20/25)。

结果

共识别出7项比较PRK(683眼)和LASIK(403眼)矫正近视的PRCT。更多接受LASIK的患者在6个月时达到UCVA≥20/20(比值比,随机效应模型[95%置信区间],1.72[1.14 - 2.58];P = 0.009)和12个月时(1.78[1.15 - 2.75],P = 0.01)。接受LASIK的患者在6个月时BSCVA下降≥2行的情况较少见(2.69[1.01 - 7.18],P = 0.05)。来自14项LASIK(7810眼)和10项PRK(4414眼)FDA激光批准病例系列的数据显示,更多接受LASIK的患者在12个月时达到UCVA 20/20或更好(1.15[1.03 - 1.29],P = 0.01),治疗后6个月(1.38[1.26 - 1.50],P<0.00001)和12个月(1.21[1.08 - 1.36],P = 0.0009)时,显著更多接受LASIK的患者的屈光度在目标屈光度±0.50 D范围内,且接受LASIK的患者在6个月时BSCVA下降≥2行的情况较少见(2.91[2.22 - 3.83],P<0.00001)。

结论

LASIK的疗效和安全性似乎优于PRK。然而,所审查的数据来自至少5年前进行的研究。因此,尚不清楚我们的研究结果与当今的方法和结果有何关联。需要进一步进行比较当代设备和技术的试验,以重新评估这些手术的相对优点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验